Rosiglitazone is a potent and selective agonist for PPAR gamma (Peroxisome proliferator-activated receptor). PPAR gamma plays a functional role in adipogenesis, it belongs to a group of nuclear receptor proteins that are essential to the regulation of cellular differentiation, development and metabolism. It activates luciferase-based expression constructs PPAR gamma1 and PPARgamma2.
Rosiglitazone is antidiabetic, working as an insulin sensitizer by binding to the PPAR gamma receptors in fat cells and making the cells more responsive to insulin. Rosiglitazone induced adipocyte differentiation in pluripotent C3H10T1/2 stem cells. It also significantly increased the differentiation of multinucleated osteoclasts.
1. Garcia-Ruiz, I., et al. 2007. Hepatology. 46(2): 414-423. PMID: 17654601
2. Zhang, XZ. 2010. Reprod Biomed Online. 21(1): 26-36. PMID: 20462797
3. Lyssiotis, Ca., et al. 2011. Angew Chem Int Ed Engl. 50(1): 200-242. PMID: 21184400
4. Wu, H., et al. 2013. J Cell Biochem. 114(9): 1969-1977. PMID: 23494891